Orient Europharma Co Ltd (4120) — Capital Reinvestment Ratio
Orient Europharma Co Ltd (4120) has a Capital Reinvestment Ratio of 2.68x as of June 2025, meaning it reinvests 3% of its operating cash flow (NT$33.25 Million) in capital expenditures (NT$89.03 Million). Check tangible net worth ratio of Orient Europharma Co Ltd to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Orient Europharma Co Ltd Capital Reinvestment Ratio (2015–2023)
This chart tracks Orient Europharma Co Ltd's Capital Reinvestment Ratio across 8 annual periods. For the full cash flow conversion analysis, see 4120 operating cash flow.
Annual Capital Reinvestment Ratio for Orient Europharma Co Ltd (2015–2023)
Year-by-year Capital Reinvestment Ratio for Orient Europharma Co Ltd from 2015 to 2023. See cash generation quality of Orient Europharma Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 1.56x | NT$64.67 Million | NT$100.70 Million | ▼ -92.3% |
| 2021 | 20.13x | NT$77.65 Million | NT$1.56 Billion | ▲ +5161.6% |
| 2020 | 0.38x | NT$608.55 Million | NT$232.78 Million | ▼ -30.4% |
| 2019 | 0.55x | NT$227.37 Million | NT$124.98 Million | ▼ -36.9% |
| 2018 | 0.87x | NT$231.31 Million | NT$201.61 Million | ▲ +42.5% |
| 2017 | 0.61x | NT$601.08 Million | NT$367.66 Million | ▼ -69.7% |
| 2016 | 2.02x | NT$111.24 Million | NT$224.81 Million | ▲ +467.0% |
| 2015 | 0.36x | NT$643.97 Million | NT$229.54 Million | — |